List of Excipients in Branded Drug CUTIVATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
PharmaDerm a division of Fougera Pharmaceuticals Inc	CUTIVATE	fluticasone propionate	10337-332	CETETH-20
PharmaDerm a division of Fougera Pharmaceuticals Inc	CUTIVATE	fluticasone propionate	10337-332	CETOSTEARYL ALCOHOL
PharmaDerm a division of Fougera Pharmaceuticals Inc	CUTIVATE	fluticasone propionate	10337-332	CITRIC ACID MONOHYDRATE
PharmaDerm a division of Fougera Pharmaceuticals Inc	CUTIVATE	fluticasone propionate	10337-332	IMIDUREA
PharmaDerm a division of Fougera Pharmaceuticals Inc	CUTIVATE	fluticasone propionate	10337-332	ISOPROPYL MYRISTATE
PharmaDerm a division of Fougera Pharmaceuticals Inc	CUTIVATE	fluticasone propionate	10337-332	MINERAL OIL

Cutivate Excipient Strategy and Commercial Opportunities for Fluticasone Propionate Topicals

Last updated: August 26, 2026

Cutivate is a topical fluticasone propionate product used for corticosteroid-responsive dermatoses. Its commercial opportunity is no longer based on molecule-level exclusivity. It is based on vehicle performance, tolerability, patient adherence, pediatric usability, manufacturing efficiency, and differentiated delivery formats.

For a developer, the highest-value excipient strategies are low-irritancy cream systems, steroid-sparing barrier-supportive vehicles, non-greasy lotions for hairy or large treatment areas, and specialized scalp or sensitive-skin presentations. A conventional generic cream has a lower technical barrier but faces price competition and limited differentiation.

What is Cutivate and which formulations use fluticasone propionate?

Cutivate contains fluticasone propionate, a high-potency topical corticosteroid. The product has been marketed in several topical dosage forms, including cream, ointment, and lotion presentations in different jurisdictions. Strengths and approved indications vary by country.

Product attribute	Typical Cutivate characteristic
Active ingredient	Fluticasone propionate
Therapeutic class	Topical corticosteroid
Common topical strength	0.05% for cream and lotion in several markets
Ointment strength	May differ by jurisdiction
Route	Cutaneous
Regulatory status	Prescription topical product
Primary use	Corticosteroid-responsive inflammatory dermatoses
Relevant patient groups	Adults and, subject to labeling, pediatric patients
Main commercial substitutes	Generic fluticasone propionate, hydrocortisone, triamcinolone, mometasone, betamethasone, branded topical corticosteroids

The vehicle is commercially important because topical corticosteroid performance depends on drug release, skin partitioning, spreadability, residence time, occlusivity, irritation, and patient willingness to use the product consistently. FDA describes topical dermatological products as complex products in which formulation and product quality can materially affect therapeutic equivalence (U.S. Food and Drug Administration [FDA], 2022).

What excipients are used in Cutivate formulations?

Cutivate excipients vary by formulation and market. Public product information identifies conventional dermatological excipients such as paraffins, fatty alcohols, glycols, water, emulsifiers, and viscosity modifiers. The precise composition must be verified against the current market-specific label before development or regulatory filing.

Cream excipient architecture

Cutivate cream-type vehicles generally use an oil-in-water emulsion structure. Common functional categories include:

Excipient category	Typical function	Commercial relevance
Liquid paraffin or mineral oil	Emolliency and occlusion	Supports spreadability and barrier feel
Cetostearyl or stearyl alcohol	Emulsification, viscosity, texture	Controls cream body and sensory profile
Isopropyl myristate	Emolliency and penetration-related vehicle behavior	Can improve slip but may be unsuitable for some acne-prone users
Propylene glycol	Humectancy, solvent function, preservation support	May cause stinging or irritation in compromised skin
Water	Continuous phase	Controls evaporation and sensory profile
Buffering agents	pH control	Supports stability and skin compatibility
Preservatives	Microbiological protection	Creates sensitivity and regulatory considerations

The commercial challenge is to retain equivalent drug release and skin delivery while improving sensory attributes. A cream that feels heavy, greasy, sticky, or irritating can reduce adherence even if it is pharmaceutically equivalent.

Ointment excipient architecture

Ointments generally rely on hydrocarbon bases such as white soft paraffin, liquid paraffin, and microcrystalline wax. These systems provide high occlusivity and may be advantageous for dry, thickened, or lichenified lesions.

Their disadvantages are practical:

• High greasiness
• Poor cosmetic acceptance
• Staining of clothing
• Reduced suitability for daytime use
• Lower acceptability on the face, scalp, or intertriginous areas

An ointment may have strong clinical utility but a narrower commercial segment. A developer can pursue an improved ointment with lower tack, better wash-off, or a more elegant semi-solid structure, but the product must preserve the intended occlusive function.

Lotion excipient architecture

Lotion formulations are better suited to large surface areas, hairy skin, and the scalp. They typically use water, alcohols or glycols, carbomers or related rheology modifiers, neutralizing agents, and emollient components.

Potential advantages include:

• Rapid spreading
• Lower residual greasiness
• Better scalp application
• Easier application over large areas
• Improved patient convenience

Potential disadvantages include stinging from alcohol or propylene glycol, drying effects, runniness, and poorer residence time. A lotion opportunity is strongest where a cream is inconvenient and an ointment is unacceptable.

How strong is the patent estate for Cutivate?

Cutivate’s original market position was based on fluticasone propionate development, formulation, and regulatory exclusivity. Those original exclusivity periods are historical. Fluticasone propionate is an established small-molecule active, and the principal commercial barrier today is generally product development and regulatory equivalence rather than new-molecule patent exclusivity.

Exclusivity issue	Current commercial significance
New chemical entity exclusivity	Expired
Original formulation patents	Expected to be expired or commercially weak in major markets
Orange Book patent blocking	Requires current FDA Orange Book verification for the specific reference product
Method-of-use patents	Usually narrow and vulnerable if directed to labeled uses or known treatment methods
Formulation patents	Potentially available for genuinely differentiated vehicles
Trade secrets	Can remain relevant for manufacturing process, scale-up, and emulsion control
Biosimilar protection	Not applicable because fluticasone propionate is a small molecule

The strongest new intellectual-property position would normally come from a specific formulation, delivery system, particle-size distribution, rheology profile, stability solution, or clinical performance advantage. A patent claiming only common excipients in ordinary concentrations would face substantial validity and obviousness risk.

What patent claims could protect a new Cutivate-type product?

Potential claim categories include:

1. A defined fluticasone propionate composition with specified excipient ranges.
2. A low-irritancy formulation with reduced or absent propylene glycol.
3. A preservative-free multidose or unit-dose package.
4. A formulation with defined in vitro release or permeation characteristics.
5. A scalp, foam, spray, gel, or film-forming delivery system.
6. A formulation with improved stability under heat or freeze-thaw conditions.
7. A vehicle designed to reduce transfer to clothing or bedding.
8. A pediatric or sensitive-skin composition with reduced sting and improved barrier compatibility.

The patent must be supported by comparative data. Useful evidence includes skin irritation testing, preservative challenge testing, IVRT, IVPT, rheology, spreadability, wash-off behavior, stability, and clinical adherence data.

What excipient strategies offer the strongest commercial opportunities?

1. Low-irritancy cream

A reduced-sting cream is the most direct opportunity. Propylene glycol, alcohols, fragrances, certain preservatives, and high levels of surfactants can create tolerability concerns in inflamed or barrier-disrupted skin.

A candidate platform could evaluate:

• Reduced propylene glycol or a replacement solvent system
• Phenoxyethanol-free or alternative preservation systems
• Lower surfactant load
• pH near the skin’s mildly acidic range
• Barrier-compatible emollients
• Lower tack after application
• Improved washability without excessive detergent content

This strategy targets eczema, facial dermatoses, and pediatric use, subject to the reference product’s labeling and the proposed product’s clinical evidence.

2. Barrier-supportive corticosteroid vehicle

A formulation combining fluticasone propionate with ceramides, fatty acids, cholesterol, glycerol, or other barrier-supportive excipients could be positioned around dry, inflamed skin. The commercial value would depend on whether the vehicle improves adherence or reduces post-treatment dryness without creating a new combination-drug regulatory burden.

The developer should distinguish between:

• A conventional generic vehicle with an emollient claim
• A composition-of-matter formulation patent
• A clinically supported barrier-repair product
• A separate over-the-counter adjunct marketed alongside the prescription product

A separate barrier-repair product may offer a simpler regulatory path than embedding multiple functional excipients in the drug product.

3. Non-greasy lotion for scalp and large areas

A lotion can address a clear usability gap between creams and ointments. Key development targets include:

• Controlled viscosity that prevents dripping
• Reduced alcohol sting
• Adequate residence time
• Low residue on hair
• Easy dosing through a pump or nozzle
• Compatibility with repeated application
• Stable suspension or solution behavior, depending on drug loading

Packaging is part of the product strategy. A metered pump or directional applicator can create meaningful differentiation even where the formula is not highly novel.

4. Foam, gel, spray, or film-forming system

Alternative dosage forms may provide stronger differentiation but create higher development risk. Foam and spray products can improve scalp coverage and application speed. Gels can reduce greasiness but may sting on fissured skin. Film-forming systems may increase residence time but raise concerns about occlusion, wash-off, accumulation, and dose uniformity.

These products are more likely to require a 505(b)(2) strategy or a complex topical equivalence program rather than a straightforward ANDA, depending on the final dosage form and reference-product relationship (FDA, 2022).

5. Preservative-free packaging

Preservative-free positioning can be commercially attractive for sensitive-skin and pediatric segments. The main technical options are:

• Unit-dose sachets
• Single-use tubes
• Airless pumps
• One-way valve systems
• Low-bioburden manufacturing with validated package protection

A preservative-free multidose package requires robust microbiological and container-closure data. The package must prevent contamination during normal use, not merely demonstrate initial sterility or low bioburden.

What FDA regulatory pathway applies to a new Cutivate product?

The pathway depends on how closely the product matches the reference product.

Product concept	Likely pathway consideration
Same active, strength, dosage form, route, and equivalent inactive ingredients	ANDA may be possible
Same active and route but materially different excipient system	ANDA feasibility requires product-specific equivalence support
New dosage form or delivery mechanism	505(b)(2) may be more appropriate
New indication or materially expanded population	May require additional clinical support
OTC switch	Requires separate FDA monograph or NDA strategy
Combination with a barrier-repair active	May create combination-product and efficacy requirements

For topical products, sameness of active ingredient is not enough. The developer may need to address Q1 sameness, Q2 sameness, Q3 characterization, comparative physical and structural properties, IVRT, IVPT, and clinical endpoint studies, depending on FDA guidance and the reference product (FDA, 2022).

The inactive ingredient strategy should be established early because changing the emulsifier, solvent, preservative, or rheology modifier can alter drug release and skin delivery.

What is the Orange Book and Paragraph IV risk for Cutivate?

Orange Book risk is product-specific. An applicant must review the current reference-listed drug entry, patent listings, exclusivity codes, and any FDA patent-listing updates before filing.

For an established fluticasone propionate topical:

• Paragraph IV risk is likely lower if no unexpired listed patents block the reference product.
• A Paragraph IV certification may still arise if an active patent is listed against a particular reference product.
• A patent challenge may target formulation claims, delivery technology, or method-of-use claims.
• A generic applicant can face litigation within the statutory filing period after a Paragraph IV notice.

The absence of an active Orange Book patent does not eliminate commercial risk. A branded or specialty-generic company could rely on non-Orange-Book patents, regulatory exclusivity for a new product, trade dress, supply agreements, or physician-directed differentiation.

Which companies are challenging or competing with Cutivate?

The competitive field includes manufacturers of generic fluticasone propionate and suppliers of alternative topical corticosteroids. The relevant competitive set includes:

• Generic fluticasone propionate cream, ointment, and lotion manufacturers
• Manufacturers of triamcinolone acetonide
• Manufacturers of mometasone furoate
• Manufacturers of betamethasone valerate or dipropionate
• Manufacturers of hydrocortisone products
• Dermatology companies selling branded nonsteroidal anti-inflammatory products
• Companies developing topical JAK inhibitors, PDE-4 inhibitors, and other steroid-sparing treatments

Competition is presentation-specific. A generic cream competes primarily on price and pharmacy availability. A scalp lotion competes on usability. A sensitive-skin cream competes on tolerability and patient preference. A barrier-supportive product competes against both prescription corticosteroids and nonprescription emollients.

What manufacturing and intellectual-property barriers affect commercialization?

Emulsion scale-up is a significant barrier. Laboratory prototypes can show acceptable appearance while failing at commercial scale because of changes in shear, heating and cooling rates, homogenization, deaeration, or addition order.

Critical process parameters include:

• Temperature during emulsification
• Mixing and homogenization energy
• Cooling rate
• Active addition stage
• Particle-size distribution
• Air incorporation
• Bulk hold time
• Filling temperature
• Tube or pump compatibility

The manufacturer should establish a control strategy linking process parameters to critical quality attributes such as viscosity, globule size, assay uniformity, drug crystallinity, preservative distribution, and IVRT performance.

Manufacturing know-how may provide stronger practical protection than a narrow excipient patent. A robust process that consistently produces equivalent drug release and stability can reduce launch risk and support contract-manufacturing partnerships.

How does Cutivate compare with generic and differentiated commercial strategies?

Strategy	Development cost	Regulatory risk	Price potential	Patent potential	Main weakness
Conventional generic cream	Low to moderate	Moderate	Low	Low	Commodity pricing
Improved low-sting cream	Moderate	Moderate	Moderate	Moderate	Requires comparative evidence
Preservative-free product	Moderate	Moderate	Moderate	Moderate	Package and microbiology burden
Scalp lotion	Moderate	Moderate to high	Moderate	Moderate	Dose delivery and stability
Foam or spray	High	High	High	High	Complex equivalence and manufacturing
Barrier-supportive formulation	Moderate to high	High	Moderate to high	High if novel	Combination and claim substantiation
Unit-dose pediatric product	Moderate	Moderate	Moderate	Moderate	Packaging cost

The most attractive risk-adjusted opportunity is usually an improved cream or lotion with a clearly measurable usability advantage. Foam and spray platforms may support higher margins but require greater clinical, regulatory, and manufacturing investment.

What generic launch scenarios exist for Cutivate?

Low-price generic launch

A manufacturer launches a Q1/Q2-matched cream or ointment and competes through wholesaler access, pharmacy substitution, and manufacturing scale. This approach has the lowest differentiation and greatest exposure to price erosion.

Specialty generic launch

A company launches a less greasy, low-sting, preservative-free, or scalp-focused product. The commercial strategy depends on obtaining favorable formulary treatment and generating prescriber awareness.

Licensed formulation launch

A drug-delivery company licenses a vehicle platform to a generic or dermatology manufacturer. The value proposition is a ready-made formulation, package, process, and equivalence package.

Geographic expansion

A company can pursue markets where Cutivate is approved under a different brand name or where fluticasone propionate topical competition is less developed. Geographic expansion requires country-specific review of formulation, excipient acceptability, labeling, trademarks, local patents, and regulatory reference products.

Key Takeaways

• Cutivate is a fluticasone propionate topical product whose current opportunity is formulation-led rather than molecule-led.
• Conventional cream, ointment, and lotion vehicles use established excipient technologies with limited standalone patent value.
• The strongest opportunities are low-sting creams, preservative-free systems, scalp lotions, and barrier-supportive vehicles.
• Propylene glycol, alcohols, preservatives, surfactants, and high-grease hydrocarbon bases are key targets for reformulation.
• FDA topical equivalence depends on more than active-ingredient sameness; Q3 characterization, IVRT, IVPT, and clinical evidence may be required.
• Biosimilar competition is irrelevant because fluticasone propionate is a small molecule.
• Generic cream launches face price erosion. Differentiated delivery systems can support better margins but carry greater regulatory and manufacturing risk.
• New patent value is most credible when tied to defined composition ranges, delivery performance, packaging, process controls, or clinically demonstrated tolerability.

FAQs

Can a fluticasone propionate cream use different excipients from Cutivate?

Yes, but the regulatory consequences depend on the degree of difference. A materially different vehicle can affect drug release, skin permeation, irritation, and therapeutic equivalence.

Is propylene glycol necessary in a Cutivate-type formulation?

No. It is useful as a solvent and humectant, but alternatives may be evaluated where reduced sting or improved tolerability is a commercial objective.

Can a preservative-free fluticasone propionate product be patented?

Potentially. Patent strength would depend on the package, microbiological-control system, composition, and supporting performance data rather than the absence of preservative alone.

Is a fluticasone propionate foam likely to have more commercial value than a cream?

It may have greater differentiation potential, especially for scalp and hairy areas, but it also presents higher equivalence, manufacturing, packaging, and stability risk.

Are Cutivate formulation patents still a major generic-entry barrier?

For an established product, the main barrier is more likely to be regulatory equivalence, manufacturing execution, and commercial access than the original molecule or formulation patents. Current Orange Book and jurisdiction-specific patent records control the legal assessment.

References

1. U.S. Food and Drug Administration. (2022). Product-specific guidance for fluticasone propionate topical products. FDA.

2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2023). Topical dermatological drug product development and regulatory considerations. FDA.

4. GlaxoSmithKline. (n.d.). Cutivate cream, ointment, and lotion product information. National and regional prescribing information.

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

6. European Medicines Agency. (n.d.). Guideline on quality and equivalence of topical products. EMA.